Data / Drug companies / Legacy Pharma USA Inc.
Legacy Pharma USA Inc.: 29 products in the FDA NDC directory, labeler code 83107
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Legacy Pharma USA Inc. (labeler code 83107) lists 29 products in the FDA National Drug Code Directory, covering 10 finished drugs by generic name. By type: 28 prescription drugs, 1 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on September 10, 2026.
The request: Watch Legacy Pharma USA Inc. (FDA labeler code 83107): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 83107
- Products in commercial distribution
- 29
- Packages
- 32
- Finished drugs by generic name
- 10
- Prescription products
- 28
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 1
- Flagged as original packager
- 27 of 27 products that carry the flag
- Started marketing in the last 12 months
- 7
- Earliest marketing start
- September 1, 2016
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 19 | 65.5% |
| Generic drugs (ANDA) | 7 | 24.1% |
| Other unapproved drugs | 2 | 6.9% |
| Drugs for further processing | 1 | 3.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 28 | 96.6% |
| Drugs for further processing | 1 | 3.4% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Hydrocortisone acetate and pramoxine hydrochloride | 9 | 2 |
| Sotalol hydrochloride | 6 | 25 |
| Tizanidine hydrochloride | 4 | 25 |
| Alosetron hydrochloride | 2 | 6 |
| Pirfenidone | 2 | 26 |
| Amifostine | 1 | 1 |
| Naftifine hydrochloride | 1 | 2 |
| Difenoxin and atropine sulfate | 1 | 2 |
| Paroxetine | 1 | 33 |
| Azathioprine | 1 | 19 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 11 | 37.9% |
| Capsule | 5 | 17.2% |
| Cream | 4 | 13.8% |
| Lotion | 3 | 10.3% |
| Ointment | 2 | 6.9% |
| Tablet, coated | 2 | 6.9% |
| Injection | 1 | 3.4% |
| Gel | 1 | 3.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Imuran | 83107-025 | Tablet | New drug applications (NDA) | September 10, 2026 |
| Pramosone | 83107-015 | Ointment | Other unapproved drugs | March 18, 2026 |
| Pramosone | 83107-014 | Ointment | Other unapproved drugs | March 18, 2026 |
| Ethyol | 83107-030 | Injection | New drug applications (NDA) | March 16, 2026 |
| Lotronex | 83107-013 | Tablet | New drug applications (NDA) | January 1, 2026 |
| Lotronex | 83107-012 | Tablet | New drug applications (NDA) | January 1, 2026 |
| Motofen | 83107-011 | Tablet | New drug applications (NDA) | January 1, 2026 |
| Naftin | 83107-023 | Gel | New drug applications (NDA) | July 29, 2025 |
| Analpram HC | 83107-019 | Cream | Generic drugs (ANDA) | July 25, 2025 |
| Pramosone Cream | 83107-017 | Cream | Generic drugs (ANDA) | June 27, 2025 |
| Pramosone Cream | 83107-016 | Cream | Generic drugs (ANDA) | June 27, 2025 |
| Analpram HC | 83107-018 | Cream | Generic drugs (ANDA) | June 23, 2025 |
| Pramosone | 83107-022 | Lotion | Generic drugs (ANDA) | June 6, 2025 |
| Esbriet | 83107-029 | Tablet, coated | New drug applications (NDA) | May 31, 2025 |
| Esbriet | 83107-028 | Tablet, coated | New drug applications (NDA) | May 31, 2025 |
| Pramosone | 83107-021 | Lotion | Generic drugs (ANDA) | May 27, 2025 |
| Analpram HC | 83107-020 | Lotion | Generic drugs (ANDA) | May 23, 2025 |
| Paroxetine | 83107-031 | Capsule | Drugs for further processing | February 18, 2025 |
| Brisdelle | 83107-027 | Capsule | New drug applications (NDA) | February 18, 2025 |
| Zanaflex | 83107-004 | Tablet | New drug applications (NDA) | August 1, 2018 |
| Zanaflex | 83107-003 | Capsule | New drug applications (NDA) | August 1, 2018 |
| Zanaflex | 83107-002 | Capsule | New drug applications (NDA) | August 1, 2018 |
| Zanaflex | 83107-001 | Capsule | New drug applications (NDA) | August 1, 2018 |
| Betapace af | 83107-010 | Tablet | New drug applications (NDA) | September 1, 2016 |
| Betapace af | 83107-009 | Tablet | New drug applications (NDA) | September 1, 2016 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.